title: Early and midterm risk of coronary allograft vasculopathy in patients bridged to orthotopic heart transplantation with ventricular assist devices.
abstract: BACKGROUND
  Coronary transplant vasculopathy (CAV) has been associated with both immunologic and nonimmunologic factors. The impact of preoperative ventricular assist device (VAD) support on the development of CAV has not been studied. To examine this, we obtained posttransplant coronary angiograms from a group of patients bridged with VAD and compared them to post transplant coronary angiograms of a non-VAD cohort.
  
  
  METHODS
  Adult patients undergoing orthotopic heart transplant between 1996-2000 were retrospectively studied and divided into VAD and non-VAD patients. Coronary angiograms were retrospectively reviewed and severity of coronary vasculopathy was categorized as trivial, mild, moderate, or severe. Other variables studied included recipient and donor demographics, cytotoxic panel reactive antibodies (PRA) against T-cell targets and flow cytometric crossmatching against donor T lymphocytes.
  
  
  RESULTS
  There was no significant difference between groups regarding demographics. However, VAD patients had a sixfold greater chance of having a T-cell PRA >10% at the time of transplant (p < 0.05), and a fourfold greater chance of having a positive cross match when compared to non-VAD patients (p < 0.05). There was no significant difference in the degree of CAV between groups. Normal coronary anatomy was present in 76% of VAD patients and 64% of non-VAD patients (p = 0.37). These results were similar at 2- and 3-year follow-up (76 vs. 74% and 80 vs. 62%, respectively).
  
  
  CONCLUSIONS
  Preoperative VAD use is associated with increased sensitization; however, these patients develop CAV at the same rate as those not bridged with a VAD.
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA. gonzalg@ccf.org
authors.forename: Gonzalo V
authors.initials: GV
authors.lastname: Gonzalez-Stawinski
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Cook
authors.forename: Albert S Y
authors.initials: AS
authors.lastname: Chang
authors.forename: Fernando
authors.initials: F
authors.lastname: Atik
authors.forename: Jose L
authors.initials: JL
authors.lastname: Navia
authors.forename: Michael
authors.initials: M
authors.lastname: Banbury
authors.forename: Eric
authors.initials: E
authors.lastname: Roselli
authors.forename: James B
authors.initials: JB
authors.lastname: Young
authors.forename: Randall A
authors.initials: RA
authors.lastname: Starling
authors.forename: Nicholas G
authors.initials: NG
authors.lastname: Smedira
mesh_terms: D001402:B-Lymphocytes / Q000276:immunology; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000453:epidemiology*; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006331:Heart Diseases / Q000601:surgery / Q000628:therapy; D016027:Heart Transplantation / Q000276:immunology / Q000473:pathology*; D006353:Heart-Assist Devices; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D014184:Transplantation, Homologous
chemical_list: D007166:Immunosuppressive Agents